MCL-1 dependency of cisplatin-resistant cancer cells

Judith Michels, Florine Obrist, Ilio Vitale, Delphine Lissa, Pauline Garcia, Parviz Behnam-Motlagh, Kimitoshi Kohno, Gen Sheng Wu, Catherine Brenner, Maria Castedo, Guido Kroemer

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The selection of human cancer cell lines in cis-diamminedichloroplatinum(II) (CDDP, best known as cisplatin) is accompanied by stereotyped alterations that contribute to the acquisition of a CDDP-resistant state. Thus, CDDP resistance often leads to the upregulation of the DNA repair enzyme poly (ADP-ribose) polymerase-1 (PARP1) with the consequent intracellular accumulation of poly (ADP-ribose) (PAR)-modified proteins. Here we report another frequent alteration accompanying CDDP resistance, namely upregulation of the antiapoptotic BCL-2 family protein MCL-1. Six out of 8 CDDP resistant cancer cell lines manifested an increase in MCL-1 protein expression level, while only a minority of cell lines overexpressed BCL-2 or BCL-XL. BCL-XL was decreased in six out of 8 cancer cell lines. Importantly, MCL-1 overexpressing, CDDP resistant cells appear to be 'addicted' to MCL-1 because they died upon depletion of MCL-1 by RNA interference or pharmacological inhibition of MCL-1 expression by the BH3 mimetic obatoclax. Knockdown of PARP1 did not succeed in reducing MCL-1 expression, while depletion or inhibition of MCL-1 failed to affect the activity of PARP1. Hence, the two resistance mechanisms are not linked to each other by a direct cause-effect relationship. Importantly, CDDP-resistant, MCL-1 overexpressing human non-small cell lung cancers responded to monotherapy with obatoclax in vivo, in xenotransplanted mice, underscoring the probable therapeutic relevance of these findings.

Original languageEnglish
Pages (from-to)55-61
Number of pages7
JournalBiochemical Pharmacology
Volume92
Issue number1
DOIs
Publication statusPublished - Nov 1 2014

Fingerprint

Cisplatin
Cells
Poly(ADP-ribose) Polymerases
Cell Line
Neoplasms
Up-Regulation
DNA Repair Enzymes
Poly Adenosine Diphosphate Ribose
Proteins
RNA Interference
Non-Small Cell Lung Carcinoma
Pharmacology
RNA
Poly (ADP-Ribose) Polymerase-1
obatoclax
Therapeutics

Keywords

  • Apoptosis
  • Chemoresistance
  • MCL-1
  • Obatoclax
  • PARP1

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry
  • Medicine(all)

Cite this

Michels, J., Obrist, F., Vitale, I., Lissa, D., Garcia, P., Behnam-Motlagh, P., ... Kroemer, G. (2014). MCL-1 dependency of cisplatin-resistant cancer cells. Biochemical Pharmacology, 92(1), 55-61. https://doi.org/10.1016/j.bcp.2014.07.029

MCL-1 dependency of cisplatin-resistant cancer cells. / Michels, Judith; Obrist, Florine; Vitale, Ilio; Lissa, Delphine; Garcia, Pauline; Behnam-Motlagh, Parviz; Kohno, Kimitoshi; Wu, Gen Sheng; Brenner, Catherine; Castedo, Maria; Kroemer, Guido.

In: Biochemical Pharmacology, Vol. 92, No. 1, 01.11.2014, p. 55-61.

Research output: Contribution to journalArticle

Michels, J, Obrist, F, Vitale, I, Lissa, D, Garcia, P, Behnam-Motlagh, P, Kohno, K, Wu, GS, Brenner, C, Castedo, M & Kroemer, G 2014, 'MCL-1 dependency of cisplatin-resistant cancer cells', Biochemical Pharmacology, vol. 92, no. 1, pp. 55-61. https://doi.org/10.1016/j.bcp.2014.07.029
Michels J, Obrist F, Vitale I, Lissa D, Garcia P, Behnam-Motlagh P et al. MCL-1 dependency of cisplatin-resistant cancer cells. Biochemical Pharmacology. 2014 Nov 1;92(1):55-61. https://doi.org/10.1016/j.bcp.2014.07.029
Michels, Judith ; Obrist, Florine ; Vitale, Ilio ; Lissa, Delphine ; Garcia, Pauline ; Behnam-Motlagh, Parviz ; Kohno, Kimitoshi ; Wu, Gen Sheng ; Brenner, Catherine ; Castedo, Maria ; Kroemer, Guido. / MCL-1 dependency of cisplatin-resistant cancer cells. In: Biochemical Pharmacology. 2014 ; Vol. 92, No. 1. pp. 55-61.
@article{b004109594114c3d91a734575c9f0673,
title = "MCL-1 dependency of cisplatin-resistant cancer cells",
abstract = "The selection of human cancer cell lines in cis-diamminedichloroplatinum(II) (CDDP, best known as cisplatin) is accompanied by stereotyped alterations that contribute to the acquisition of a CDDP-resistant state. Thus, CDDP resistance often leads to the upregulation of the DNA repair enzyme poly (ADP-ribose) polymerase-1 (PARP1) with the consequent intracellular accumulation of poly (ADP-ribose) (PAR)-modified proteins. Here we report another frequent alteration accompanying CDDP resistance, namely upregulation of the antiapoptotic BCL-2 family protein MCL-1. Six out of 8 CDDP resistant cancer cell lines manifested an increase in MCL-1 protein expression level, while only a minority of cell lines overexpressed BCL-2 or BCL-XL. BCL-XL was decreased in six out of 8 cancer cell lines. Importantly, MCL-1 overexpressing, CDDP resistant cells appear to be 'addicted' to MCL-1 because they died upon depletion of MCL-1 by RNA interference or pharmacological inhibition of MCL-1 expression by the BH3 mimetic obatoclax. Knockdown of PARP1 did not succeed in reducing MCL-1 expression, while depletion or inhibition of MCL-1 failed to affect the activity of PARP1. Hence, the two resistance mechanisms are not linked to each other by a direct cause-effect relationship. Importantly, CDDP-resistant, MCL-1 overexpressing human non-small cell lung cancers responded to monotherapy with obatoclax in vivo, in xenotransplanted mice, underscoring the probable therapeutic relevance of these findings.",
keywords = "Apoptosis, Chemoresistance, MCL-1, Obatoclax, PARP1",
author = "Judith Michels and Florine Obrist and Ilio Vitale and Delphine Lissa and Pauline Garcia and Parviz Behnam-Motlagh and Kimitoshi Kohno and Wu, {Gen Sheng} and Catherine Brenner and Maria Castedo and Guido Kroemer",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.bcp.2014.07.029",
language = "English",
volume = "92",
pages = "55--61",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - MCL-1 dependency of cisplatin-resistant cancer cells

AU - Michels, Judith

AU - Obrist, Florine

AU - Vitale, Ilio

AU - Lissa, Delphine

AU - Garcia, Pauline

AU - Behnam-Motlagh, Parviz

AU - Kohno, Kimitoshi

AU - Wu, Gen Sheng

AU - Brenner, Catherine

AU - Castedo, Maria

AU - Kroemer, Guido

PY - 2014/11/1

Y1 - 2014/11/1

N2 - The selection of human cancer cell lines in cis-diamminedichloroplatinum(II) (CDDP, best known as cisplatin) is accompanied by stereotyped alterations that contribute to the acquisition of a CDDP-resistant state. Thus, CDDP resistance often leads to the upregulation of the DNA repair enzyme poly (ADP-ribose) polymerase-1 (PARP1) with the consequent intracellular accumulation of poly (ADP-ribose) (PAR)-modified proteins. Here we report another frequent alteration accompanying CDDP resistance, namely upregulation of the antiapoptotic BCL-2 family protein MCL-1. Six out of 8 CDDP resistant cancer cell lines manifested an increase in MCL-1 protein expression level, while only a minority of cell lines overexpressed BCL-2 or BCL-XL. BCL-XL was decreased in six out of 8 cancer cell lines. Importantly, MCL-1 overexpressing, CDDP resistant cells appear to be 'addicted' to MCL-1 because they died upon depletion of MCL-1 by RNA interference or pharmacological inhibition of MCL-1 expression by the BH3 mimetic obatoclax. Knockdown of PARP1 did not succeed in reducing MCL-1 expression, while depletion or inhibition of MCL-1 failed to affect the activity of PARP1. Hence, the two resistance mechanisms are not linked to each other by a direct cause-effect relationship. Importantly, CDDP-resistant, MCL-1 overexpressing human non-small cell lung cancers responded to monotherapy with obatoclax in vivo, in xenotransplanted mice, underscoring the probable therapeutic relevance of these findings.

AB - The selection of human cancer cell lines in cis-diamminedichloroplatinum(II) (CDDP, best known as cisplatin) is accompanied by stereotyped alterations that contribute to the acquisition of a CDDP-resistant state. Thus, CDDP resistance often leads to the upregulation of the DNA repair enzyme poly (ADP-ribose) polymerase-1 (PARP1) with the consequent intracellular accumulation of poly (ADP-ribose) (PAR)-modified proteins. Here we report another frequent alteration accompanying CDDP resistance, namely upregulation of the antiapoptotic BCL-2 family protein MCL-1. Six out of 8 CDDP resistant cancer cell lines manifested an increase in MCL-1 protein expression level, while only a minority of cell lines overexpressed BCL-2 or BCL-XL. BCL-XL was decreased in six out of 8 cancer cell lines. Importantly, MCL-1 overexpressing, CDDP resistant cells appear to be 'addicted' to MCL-1 because they died upon depletion of MCL-1 by RNA interference or pharmacological inhibition of MCL-1 expression by the BH3 mimetic obatoclax. Knockdown of PARP1 did not succeed in reducing MCL-1 expression, while depletion or inhibition of MCL-1 failed to affect the activity of PARP1. Hence, the two resistance mechanisms are not linked to each other by a direct cause-effect relationship. Importantly, CDDP-resistant, MCL-1 overexpressing human non-small cell lung cancers responded to monotherapy with obatoclax in vivo, in xenotransplanted mice, underscoring the probable therapeutic relevance of these findings.

KW - Apoptosis

KW - Chemoresistance

KW - MCL-1

KW - Obatoclax

KW - PARP1

UR - http://www.scopus.com/inward/record.url?scp=84908303131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908303131&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2014.07.029

DO - 10.1016/j.bcp.2014.07.029

M3 - Article

C2 - 25107702

AN - SCOPUS:84908303131

VL - 92

SP - 55

EP - 61

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 1

ER -